Aims And Method: Catatonia has been increasingly described in cases of COVID-19; we therefore aimed to investigate the evidence for catatonia in patients with COVID-19. We searched PubMed, EMBASE, PsycINFO, BIN and CINAHL databases for articles published in English, from the initial descriptions of the COVID-19 pandemic to January 2022.
Results: A total 204 studies were identified, 27 (13%) of which met the inclusion criteria. The evidence available was based on case reports. The articles included in this review identified a total of 42 patients, ranging from the ages of 12 to ≥70 years, with confirmed or possible catatonia during or after a COVID-19 infection.
Clinical Implications: This review provides valuable information to clinicians in medical practice for treating patients with COVID-19, and a foundation for further research for this uncommon syndrome of COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387440 | PMC |
| http://dx.doi.org/10.1192/bjb.2022.30 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catatonia Associated With Post-Acute COVID-19 in a Young Child.
Prim Care Companion CNS Disord
January 2025
Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.
Pharmacotherapy
October 2024
Houston Methodist Hospital, Houston, Texas, USA.
Article Synopsis
- Benzodiazepines and ECT are primary treatments for catatonia, which can arise from psychiatric or medical conditions, but when they're ineffective, ketamine has been explored as an alternative therapy.
- A case study highlighted a 77-year-old woman with treatment-resistant catatonia due to schizophrenia, who showed a rapid recovery after a single ketamine infusion when ECT was unavailable during the pandemic.
- While ketamine may be a promising option for drug-resistant catatonia, it needs to be used carefully because it could potentially worsen psychosis in patients with schizophrenia, indicating the need for more research in this area.
Catatonia responsive to corticosteroids in a patient with an SCN2A variant.
Am J Med Genet C Semin Med Genet
December 2024
Division of Child & Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Variants in SCN2A are a known risk factor for developing autism spectrum disorder (ASD). Catatonia is a complex neuropsychiatric syndrome, which occurs at a higher rate in individuals with ASD. Catatonia has also been associated with COVID-19 infection, though the majority of these cases are associated with increased serum inflammatory markers.
View Article and Find Full Text PDFNew-onset schizophrenia in an adolescent after COVID-19.
J Nippon Med Sch
June 2024
Department of Neuropsychiatry, Nippon Medical School Musashi Kosugi Hospital.
Schizophrenia develops during adolescence. Maternal infections during the fetal period increase the incidence of schizophrenia in children, which suggests that the pathogenesis involves neuroinflammation. Here, we report a case of new-onset schizophrenia in a 16-year-old boy after COVID-19.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!